# AURIGA (NCT03901963)

> A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03901963
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Daratumumab; Lenalidomide
- Enrollment: 200
- Primary outcome: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 53
- YouTube: 44
- Podcasts: 18

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=auriga-nct03901963

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03901963", "email": "<work email>"}; the inbox owner confirms by the emailed link.